{ "access": { "embargo": { "active": false, "reason": null }, "files": "public", "record": "public", "status": "open" }, "created": "2026-02-02T03:13:50.013252+00:00", "custom_fields": {}, "deletion_status": { "is_deleted": false, "status": "P" }, "files": { "count": 1, "default_preview": "The Influence of the Pharmaceutical Industry.pdf", "enabled": true, "entries": { "The Influence of the Pharmaceutical Industry.pdf": { "access": { "hidden": false }, "checksum": "md5:768cc8b21570e9970a3c3476adf42fa6", "ext": "pdf", "id": "6850388d-9fcf-41e7-bb1a-f55a4f43fab5", "key": "The Influence of the Pharmaceutical Industry.pdf", "links": { "content": "https://zenodo.org/api/records/18452853/files/The%20Influence%20of%20the%20Pharmaceutical%20Industry.pdf/content", "iiif_api": "https://zenodo.org/api/iiif/record:18452853:The%20Influence%20of%20the%20Pharmaceutical%20Industry.pdf/full/full/0/default.png", "iiif_base": "https://zenodo.org/api/iiif/record:18452853:The%20Influence%20of%20the%20Pharmaceutical%20Industry.pdf", "iiif_canvas": "https://zenodo.org/api/iiif/record:18452853/canvas/The%20Influence%20of%20the%20Pharmaceutical%20Industry.pdf", "iiif_info": "https://zenodo.org/api/iiif/record:18452853:The%20Influence%20of%20the%20Pharmaceutical%20Industry.pdf/info.json", "self": "https://zenodo.org/api/records/18452853/files/The%20Influence%20of%20the%20Pharmaceutical%20Industry.pdf" }, "metadata": { "height": 842, "width": 595 }, "mimetype": "application/pdf", "size": 343378, "storage_class": "L" } }, "order": [], "total_bytes": 343378 }, "id": "18452853", "is_draft": false, "is_published": true, "links": { "access": "https://zenodo.org/api/records/18452853/access", "access_grants": "https://zenodo.org/api/records/18452853/access/grants", "access_links": "https://zenodo.org/api/records/18452853/access/links", "access_request": "https://zenodo.org/api/records/18452853/access/request", "access_users": "https://zenodo.org/api/records/18452853/access/users", "archive": "https://zenodo.org/api/records/18452853/files-archive", "archive_media": "https://zenodo.org/api/records/18452853/media-files-archive", "communities": "https://zenodo.org/api/records/18452853/communities", "communities-suggestions": "https://zenodo.org/api/records/18452853/communities-suggestions", "doi": "https://doi.org/10.5281/zenodo.18452853", "draft": "https://zenodo.org/api/records/18452853/draft", "file_modification": "https://zenodo.org/api/records/18452853/file-modification", "files": "https://zenodo.org/api/records/18452853/files", "latest": "https://zenodo.org/api/records/18452853/versions/latest", "latest_html": "https://zenodo.org/records/18452853/latest", "media_files": "https://zenodo.org/api/records/18452853/media-files", "parent": "https://zenodo.org/api/records/18452852", "parent_doi": "https://doi.org/10.5281/zenodo.18452852", "parent_doi_html": "https://zenodo.org/doi/10.5281/zenodo.18452852", "parent_html": "https://zenodo.org/records/18452852", "preview_html": "https://zenodo.org/records/18452853?preview=1", "quota_increase": "https://zenodo.org/api/records/18452853/quota-increase", "request_deletion": "https://zenodo.org/api/records/18452853/request-deletion", "requests": "https://zenodo.org/api/records/18452853/requests", "reserve_doi": "https://zenodo.org/api/records/18452853/draft/pids/doi", "self": "https://zenodo.org/api/records/18452853", "self_doi": "https://doi.org/10.5281/zenodo.18452853", "self_doi_html": "https://zenodo.org/doi/10.5281/zenodo.18452853", "self_html": "https://zenodo.org/records/18452853", "self_iiif_manifest": "https://zenodo.org/api/iiif/record:18452853/manifest", "self_iiif_sequence": "https://zenodo.org/api/iiif/record:18452853/sequence/default", "thumbnails": { "10": "https://zenodo.org/api/iiif/record:18452853:The%20Influence%20of%20the%20Pharmaceutical%20Industry.pdf/full/%5E10,/0/default.jpg", "100": "https://zenodo.org/api/iiif/record:18452853:The%20Influence%20of%20the%20Pharmaceutical%20Industry.pdf/full/%5E100,/0/default.jpg", "1200": "https://zenodo.org/api/iiif/record:18452853:The%20Influence%20of%20the%20Pharmaceutical%20Industry.pdf/full/%5E1200,/0/default.jpg", "250": "https://zenodo.org/api/iiif/record:18452853:The%20Influence%20of%20the%20Pharmaceutical%20Industry.pdf/full/%5E250,/0/default.jpg", "50": "https://zenodo.org/api/iiif/record:18452853:The%20Influence%20of%20the%20Pharmaceutical%20Industry.pdf/full/%5E50,/0/default.jpg", "750": "https://zenodo.org/api/iiif/record:18452853:The%20Influence%20of%20the%20Pharmaceutical%20Industry.pdf/full/%5E750,/0/default.jpg" }, "versions": "https://zenodo.org/api/records/18452853/versions" }, "media_files": { "count": 1, "enabled": true, "entries": { "The Influence of the Pharmaceutical Industry.pdf.ptif": { "access": { "hidden": true }, "ext": "ptif", "id": "4e505691-a3ed-4705-abd7-26039140d853", "key": "The Influence of the Pharmaceutical Industry.pdf.ptif", "links": { "content": "https://zenodo.org/api/records/18452853/files/The%20Influence%20of%20the%20Pharmaceutical%20Industry.pdf.ptif/content", "self": "https://zenodo.org/api/records/18452853/files/The%20Influence%20of%20the%20Pharmaceutical%20Industry.pdf.ptif" }, "metadata": null, "mimetype": "application/octet-stream", "processor": { "source_file_id": "6850388d-9fcf-41e7-bb1a-f55a4f43fab5", "status": "finished", "type": "image-tiles" }, "size": 0, "storage_class": "L" } }, "order": [], "total_bytes": 0 }, "metadata": { "creators": [ { "person_or_org": { "family_name": "Stacciarini", "given_name": "Jo\u00e3o", "identifiers": [ { "identifier": "0000-0003-3517-9410", "scheme": "orcid" } ], "name": "Stacciarini, Jo\u00e3o", "type": "personal" } } ], "description": "

Over the past century, the pharmaceutical industry has consolidated itself as one of the most influential sectors of the global economy, exerting impacts that extend beyond production and reach scientific research, clinical practice, and health-related decision-making processes. Beyond the scientific and technological advances that have driven its expansion, critical scholarship has emphasized the adoption of structural mechanisms of corporate influence capable of shaping public policies, research agendas, and therapeutic guidance. This scientific report analyzes, in a concise and accessible manner, three central dimensions of this phenomenon: the influence of the pharmaceutical industry on regulatory and oversight agencies, patient organizations, and the development of clinical guidelines. Drawing on empirical evidence, case studies, and data from the international literature, the analysis examines the recurrence of financial conflicts of interest in regulatory committees, the systematic funding of patient associations, and the financial ties between authors of medical guidelines and pharmaceutical companies. The evidence presented demonstrates that these practices do not represent isolated episodes, but rather institutionalized arrangements with cumulative effects on regulatory decisions, public narratives surrounding disease, and global prescribing patterns. By rendering these mechanisms visible, the report contributes to ongoing public debate on transparency, health governance, and the contemporary challenges posed by a sector characterized by high profitability, power asymmetries, and expanding influence over health systems.

", "publication_date": "2026-02-02", "publisher": "Zenodo", "references": [ { "reference": "STACCIARINI, Jo\u00e3o Henrique Santana. Influence, Deviations, and Excesses in the Pharmaceutical Sector. SocArXi, Center for Open Science, 2026. https://doi.org/10.31235/osf.io/rbysc_v1." }, { "reference": "STACCIARINI, Jo\u00e3o Henrique Santana. The Consolidation of the Pharmaceutical Sector in the Global Economy: growth, influence, deviations, and marketing. 2023. 145 p. PhD Thesis - Geography, Federal University of Goi\u00e1s, Goi\u00e2nia (Brazil), 2023. https://doi.org/10.5281/zenodo.10377840." }, { "reference": "PINA, Ana Sofia; HUSSAIN, Abid; ROQUE, Ana Cec\u00edlia A.. An Historical Overview of Drug Discovery. Methods in Molecular Biology, [S.L.], p. 3-12, oct. 2009. http://dx.doi.org/10.1007/978-1-60761-244-5_1." }, { "reference": "STACCIARINI, Jo\u00e3o Henrique Santana. The Global Pharmaceutical Sector: numbers and dynamics. SocArXiv, Center for Open Science. 2024. https://doi.org/10.31235/osf.io/hbs8j." }, { "reference": "STACCIARINI, Jo\u00e3o Henrique Santana. Power, Disputes, and Geopolitics in the Pharmaceutical Sector. SocArXiv, Center for Open Science. 2024. https://doi.org/10.31235/osf.io/z5mf6_v2." }, { "reference": "MALERBA, Franco; ORSENIGO, Luigi. The evolution of the pharmaceutical industry. Business History, [S.L.], v. 57, n. 5, p. 664-687, 3 jun. 2015. http://dx.doi.org/10.1080/00076791.2014.975119." }, { "reference": "DIMASI, Joseph A. et al. Innovation in the pharmaceutical industry: new estimates of r&d costs. Journal Of Health Economics, [S.L.], v. 47, p. 20-33, may. 2016. http://dx.doi.org/10.1016/j.jhealeco.2016.01.012." }, { "reference": "STACCIARINI, Jo\u00e3o Henrique Santana. Research and Development (R&D) in the Pharmaceutical Sector. Revista Terceiro Inclu\u00eddo, [S.L.], v. 14, n. 1, p. 14109, 6 aug. 2024. http://dx.doi.org/10.5216/teri.v14i1.79594." }, { "reference": "TANNOURY, Maya; ATTIEH, Zouhair. The Influence of Emerging Markets on the Pharmaceutical Industry. Current Therapeutic Research, [S.L.], v. 86, p. 19-22, 2017. http://dx.doi.org/10.1016/j.curtheres.2017.04.005." }, { "reference": "OECD. Health at a Glance 2021: OECD indicators. Paris, France: OECD Publishing, 2021. 274 p. https://doi.org/10.1787/ae3016b9-en." }, { "reference": "FDA - Food and Drug Administration (FDA). Advisory Committees. Federal agency of the Department of Health and Human Services (USA). 2023. Available: https://www.fda.gov/advisory-committees. Accessed on: 10 apr. 2023." }, { "reference": "HAYES, Michael J.; PRASAD, Vinay. Financial Conflicts of Interest at FDA Drug Advisory Committee Meetings. Hastings Center Report, [S.L.], v. 48, n. 2, p. 10-13, mar. 2018. http://dx.doi.org/10.1002/hast.833." }, { "reference": "HIGHAM, Scott; BERNSTEIN, Lenny. The Drug Industry's Triumph over the DEA. The Washington Post. Washington, D.C., U.S. out. 2017. Available: https://www.washingtonpost.com/graphics/2017/investigations/dea-drug-industry-congress/. Accessed on: 26 nov. 2025." }, { "reference": "LURIE, Peter et al. Financial Conflict of Interest Disclosure and Voting Patterns at Food and Drug Administration Drug Advisory Committee Meetings. JAMA, v. 295, n. 16, apr. 2006. http://dx.doi.org/10.1001/jama.295.16.1921." }, { "reference": "PHAM-KANTER, Genevieve. Revisiting Financial Conflicts of Interest in FDA Advisory Committees. Milbank Quarterly, [S.L.], v. 92, n. 3, p. 446-470, sep. 2014. http://dx.doi.org/10.1111/1468-0009.12073." }, { "reference": "NEJSTGAARD, Camilla H et al. Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review. BMJ, [S.L.], p. 1-12, dec. 2020. http://dx.doi.org/10.1136/bmj.m4234." }, { "reference": "HARRIS, Gardiner; BERENSON, Alex. 10 Voters on Panel Backing Pain Pills Had Industry Ties. The New York Times. 2005. Available: https://www.nytimes.com/2005/02/25/politics/10-voters-on-panel-backing-pain-pills-had-industry-ties.html. Accessed on: 26 nov. 2025." }, { "reference": "MUKHERJEE, Debabrata et al. Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors. Jama, [S.L.], v. 286, n. 8, p. 954, aug. 2001. http://dx.doi.org/10.1001/jama.286.8.954." }, { "reference": "GRAHAM, David J et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. The Lancet, [S.L.], v. 365, n. 9458, p. 475-481, feb. 2005. http://dx.doi.org/10.1016/s0140-6736(05)17864-7." }, { "reference": "NYT - The New York Times. Experts and the Drug Industry. Opinion: Editorial. 2005. Available: https://www.nytimes.com/2005/03/04/opinion/experts-and-the-drug-industry.html. Accessed on: 27 oct. 2025." }, { "reference": "TOPOL, Eric J.. Failing the Public Health \u2013 Rofecoxib, Merck, and the FDA. New England Journal of Medicine, [S.L.], v. 351, n. 17, p. 1707-1709, oct. 2004. http://dx.doi.org/10.1056/nejmp048286." }, { "reference": "REUTERS - News Agency. Merck Sees Slightly Higher 2007 Earnings. The New York Times. 2006. Available: https://www.nytimes.com/2006/12/07/business/07drug.html. Accessed on: 27 oct. 2025." }, { "reference": "23.PFIZER - Financial Report (2004). New York, NY: Pfizer, 2005. 67 p. Available: https://truecostofhealthcare.org/wp-content/uploads/2015/01/Pfizer_2004.87220720.pdf. Accessed on: 10 abr. 2023." }, { "reference": "MCCOY, Matthew S. et al. Conflicts of Interest for Patient-Advocacy Organizations. New England Journal of Medicine, [S.L.], v. 376, n. 9, p. 880-885, 2 mar. 2017. http://dx.doi.org/10.1056/nejmsr1610625." }, { "reference": "LEXCHIN, Joel et al. National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study. BMJ Open, v. 12, n. 3, mar. 2022. http://dx.doi.org/10.1136/bmjopen-2021-055287." }, { "reference": "OZIERANSKI, Piotr et al. Exposing drug industry funding of UK patient organisations. BMJ, [S.L.], p. 1-9, 22 may. 2019. http://dx.doi.org/10.1136/bmj.l1806." }, { "reference": "COLOMBO, Cinzia et al. Patient Organizations Funding from Pharmaceutical Companies: is disclosure clear, complete and accessible to the public? an Italian survey. Plos One, v. 7, n. 5. 2012. http://dx.doi.org/10.1371/journal.pone.0034974." }, { "reference": "HEMMINKI, Elina et al. Co-operation between patient organisations and the drug industry in Finland. Social Science & Medicine, [S.L.], v. 70, n. 8, p. 1171, apr. 2010. http://dx.doi.org/10.1016/j.socscimed.2010.01.005." }, { "reference": "MULINARI, Shai et al. Five years of pharmaceutical industry funding of patient organisations in Sweden: cross-sectional study of companies, patient organisations and drugs. Plos One, v. 15, n. 6, jun. 2020. http://dx.doi.org/10.1371/journal.pone.0235021." }, { "reference": "KARAS, Laura et al. Pharmaceutical Industry Funding to Patient-Advocacy Organization: a cross-national comparison of disclosure codes and regulation. Hastings International and Comparative Law Review, EUA, v. 42, n. 2, p. 453, mar. 2019. Available: https://repository.uchastings.edu/hastings_international_comparative_law_review/vol42/iss2/3/. Accessed on: 26 nov. 2025." }, { "reference": "BATT, Sharon. How Big Pharma hijacked patient groups to keep drug prices high. The Breach. 2022. Available: https://breachmedia.ca/how-big-pharma-took-over-patient-groups-to-keep-drug-prices-high/. Accessed on: 28 nov. 2025." }, { "reference": "KOPP, Emily et al. Patient Advocacy Groups Take in Millions from Drugmakers. Is There a Payback? KFF Health News. 2018. Available: https://kffhealthnews.org/news/patient-advocacy-groups-take-in-millions-from-drugmakers-is-there-a-payback/. Accessed on: 26 nov. 2025." }, { "reference": "GOODRX - American healthcare company. Humira (adalimumab): Basics, Side Effects, Reviews & More. 2023. Available: https://www.goodrx.com/humira/what-is. Acesso em: 17 apr. 2023." }, { "reference": "ABBVIE - Annual Reports (2010 - 2022). North Chicago, Illinois, EUA: AbbVie, 2023. Available: https://investors.abbvie.com/annual-report-proxy. Accessed on: 17 apr. 2023." }, { "reference": "ROBBINS, Rebecca. How a Drug Company Made $114 Billion by Gaming the U.S. Patent System. The New York Times. 2023. Available: https://www.nytimes.com/2023/01/28/business/humira-abbvie-monopoly.html. Accessed on: 27 oct. 2025." }, { "reference": "TABATABAVAKILI, Sahar et al. Financial Conflicts of Interest in Clinical Practice Guidelines: a systematic review. Mayo Clinic Proceedings, v. 5, n. 2, p. 466-475, apr. 2021. http://dx.doi.org/10.1016/j.mayocpiqo.2020.09.016." }, { "reference": "CHOUDHRY, Niteesh K. et al. Relationships Between Authors of Clinical Practice Guidelines and the Pharmaceutical Industry. Jama, [S.L.], v. 287, n. 5, p. 612, feb. 2002. http://dx.doi.org/10.1001/jama.287.5.612." }, { "reference": "NEUMAN, J. et al. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study. BMJ, v. 343, n. 112, p. 1-8, oct. 2011. http://dx.doi.org/10.1136/bmj.d5621." }, { "reference": "BINDSLEV, Julie Bolette Brix et al. Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study. BMC Medical Ethics, [S.L.], v. 14, n. 1, p. 1, 3 may. 2013. http://dx.doi.org/10.1186/1472-6939-14-19." }, { "reference": "MITCHELL, Aaron P. et al. Financial Relationships with Industry Among National Comprehensive Cancer Network Guideline Authors. Jama Oncology, v. 2, n. 12, p. 1628, dec. 2016. http://dx.doi.org/10.1001/jamaoncol.2016.2710." } ], "resource_type": { "id": "publication", "title": { "de": "Publikation", "en": "Publication" } }, "rights": [ { "description": { "en": "The Creative Commons Attribution license allows re-distribution and re-use of a licensed work on the condition that the creator is appropriately credited." }, "icon": "cc-by-icon", "id": "cc-by-4.0", "props": { "scheme": "spdx", "url": "https://creativecommons.org/licenses/by/4.0/legalcode" }, "title": { "en": "Creative Commons Attribution 4.0 International" } } ], "subjects": [ { "subject": "Corporate influence" }, { "subject": "Health regulation" }, { "subject": "Conflicts of interest" }, { "subject": "Regulatory agencies" }, { "subject": "Corporate financing" }, { "subject": "Health governance" }, { "subject": "Public health policy" }, { "subject": "Regulatory capture" }, { "subject": "Collective health" } ], "title": "The Influence of the Pharmaceutical Industry on Regulatory Agencies, Patient Organizations, and Clinical Guidelines" }, "parent": { "access": { "owned_by": { "user": "1042055" }, "settings": { "accept_conditions_text": null, "allow_guest_requests": false, "allow_user_requests": false, "secret_link_expiration": 0 } }, "communities": {}, "id": "18452852", "pids": { "doi": { "client": "datacite", "identifier": "10.5281/zenodo.18452852", "provider": "datacite" } } }, "pids": { "doi": { "client": "datacite", "identifier": "10.5281/zenodo.18452853", "provider": "datacite" }, "oai": { "identifier": "oai:zenodo.org:18452853", "provider": "oai" } }, "revision_id": 4, "stats": { "all_versions": { "data_volume": 20946058.0, "downloads": 61, "unique_downloads": 40, "unique_views": 124, "views": 137 }, "this_version": { "data_volume": 20946058.0, "downloads": 61, "unique_downloads": 40, "unique_views": 124, "views": 137 } }, "status": "published", "swh": {}, "updated": "2026-02-02T03:13:50.302303+00:00", "versions": { "index": 1, "is_latest": true } }